Skip to content

Economic Evaluation

Identifying the effect of expenditure on health outcomes: another small comment on Claxton et al

In a previous post I asked whether the study by Claxton et al can or should inform the cost-effectiveness threshold used by NICE. The authors argued that, “it is the expected health effects … of the average displacement within the… Read More »Identifying the effect of expenditure on health outcomes: another small comment on Claxton et al

Do we really need to change the cost-effectiveness threshold?

The cost-effectiveness threshold utilised by health technology assessment agencies, such as NICE in the United Kingdom, below which new medical technologies and interventions are considered cost-effective, is frequently discussed. NICE currently use a threshold of £20,000 to £30,000 per quality… Read More »Do we really need to change the cost-effectiveness threshold?

Bayesian evidence synthesis and bootstrapping for trial-based economic evaluations: comfortable bed fellows?

By Mohsen Sadatsafavi and Stirling Bryan In economic evaluation of health technologies, evidence synthesis is typically about quantification of the evidence in terms of parameters. Bootstrapping is a non-parametric inferential method in trial-based economic evaluations. On the surface the two… Read More »Bayesian evidence synthesis and bootstrapping for trial-based economic evaluations: comfortable bed fellows?